Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls.


Fletcher, O; Johnson, N; dos Santos Silva, I; Orr, N; Ashworth, A; Nevanlinna, H; Heikkinen, T; Aittomäki, K; Blomqvist, C; Burwinkel, B; Bartram, CR; Meindl, A; Schmutzler, RK; Cox, A; Brock, I; Elliott, G; Reed, MW; Southey, MC; Smith, L; Spurdle, AB; Hopper, JL; Couch, FJ; Olson, JE; Wang, X; Fredericksen, Z; Schürmann, P; Waltes, R; Bremer, M; Dörk, T; Devilee, P; van Asperen, CJ; Tollenaar, RA; Seynaeve, C; Hall, P; Czene, K; Humphreys, K; Liu, J; Ahmed, S; Dunning, AM; Maranian, M; Pharoah, PD; Chenevix-Trench, G; kConFab Investigators, ; AOCS Group, ; Beesley, J; Bogdanova, NV; Antonenkova, NN; Zalutsky, IV; Anton-Culver, H; Ziogas, A; Brauch, H; Ko, YD; Hamann, U; GENICA Consortium, ; Fasching, PA; Strick, R; Ekici, AB; Beckmann, MW; Giles, GG; Severi, G; Baglietto, L; English, DR; Milne, RL; Benítez, J; Arias, JI; Pita, G; Nordestgaard, BG; Bojesen, SE; Flyger, H; Kang, D; Yoo, KY; Noh, DY; Mannermaa, A; Kataja, V; Kosma, VM; García-Closas, M; Chanock, S; Lissowska, J; Brinton, LA; Chang-Claude, J; Wang-Gohrke, S; Broeks, A; Schmidt, MK; van Leeuwen, FE; Van't Veer, LJ; Margolin, S; Lindblom, A; Humphreys, MK; Morrison, J; Platte, R; Easton, DF; Peto, J; Breast Cancer Association Consortium, ; (2010) Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. Cancer epidemiology, biomarkers & prevention, 19 (9). pp. 2143-51. ISSN 1055-9965 DOI: https://doi.org/10.1158/1055-9965.EPI-10-0374

Full text not available from this repository.

Abstract

BACKGROUND: Truncating mutations in ATM have been shown to increase the risk of breast cancer but the effect of missense variants remains contentious. METHODS: We have genotyped five polymorphic (minor allele frequency, 0.9-2.6%) missense single nucleotide polymorphisms (SNP) in ATM (S49C, S707P, F858L, P1054R, and L1420F) in 26,101 breast cancer cases and 29,842 controls from 23 studies in the Breast Cancer Association Consortium. RESULTS: Combining the data from all five SNPs, the odds ratio (OR) was 1.05 for being a heterozygote for any of the SNPs and 1.51 for being a rare homozygote for any of the SNPs with an overall trend OR of 1.06 (P(trend) = 0.04). The trend OR among bilateral and familial cases was 1.12 (95% confidence interval, 1.02-1.23; P(trend) = 0.02). CONCLUSIONS: In this large combined analysis, these five missense ATM SNPs were associated with a small increased risk of breast cancer, explaining an estimated 0.03% of the excess familial risk of breast cancer. IMPACT: Testing the combined effects of rare missense variants in known breast cancer genes in large collaborative studies should clarify their overall contribution to breast cancer susceptibility.

Item Type: Article
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Non-Communicable Disease Epidemiology
Faculty of Epidemiology and Population Health > Dept of Medical Statistics
Research Centre: Centre for Global Non-Communicable Diseases (NCDs)
PubMed ID: 20826828
Web of Science ID: 281683800004
URI: http://researchonline.lshtm.ac.uk/id/eprint/2406

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
305Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item